Sydnexis, Inc. has announced that the U.S. Food and Drug Administration will convene an Advisory Committee to review its drug candidate, SYD-101. This development follows the FDA's initial rejection of the low-dose atropine therapy designed to treat pediatric progressive myopia (PPM). The upcoming meeting marks a significant step forward in addressing the growing vision health crisis among children.
A Renewed Path for SYD-101
The decision to hold a meeting comes after Sydnexis submitted a Formal Dispute Resolution Request in response to a Complete Response Letter issued in October 2025. The advisory panel will be tasked with discussing various aspects of the company's application, with a focus on the findings from its Phase 3 STAR study. This review offers a renewed opportunity for the therapy to gain regulatory clearance in the United States.
Examining the Clinical Evidence
The Phase 3 STAR trial represents the largest global clinical program conducted for pediatric myopia to date, enrolling 847 children between the ages of three and fourteen. Participants were randomized to receive either a placebo or SYD-101 0.01% to evaluate its effectiveness in slowing myopia progression. The study was designed to provide robust evidence for the drug's potential benefits in a diverse pediatric population.
According to Sydnexis, the trial successfully achieved its primary and key secondary endpoints, demonstrating a statistically significant reduction in myopia progression. Furthermore, SYD-101 was reported to be well tolerated, with no unexpected atropine-related adverse events observed during the study. These positive safety and efficacy results will be central to the company's presentation to the FDA's advisory panel.
The Urgent Need for an Approved Treatment
Currently, many U.S. physicians use compounded low-dose atropine to manage PPM, but these formulations are not FDA-approved. This lack of regulatory oversight raises concerns about product safety, manufacturing consistency, and overall effectiveness. An approved pharmaceutical would provide a standardized and reliable treatment option for clinicians and their patients.
Medical experts have voiced strong support for a regulated therapy, citing the limitations of current options. The American Association for Pediatric Ophthalmology and Strabismus highlighted the need for consistent manufacturing standards and labeling. This sentiment was echoed in a Citizen Petition signed by over 1,000 eye care professionals urging the FDA to expedite its review.
Global Context and Future Implications
SYD-101 is already approved for use in the European Union and the United Kingdom, where it is marketed as Ryjunea®. This existing international regulatory approval provides a precedent for the drug's safety and efficacy profile. The outcome of the U.S. advisory meeting could align the nation's standard of care with that of its European counterparts.
Pediatric progressive myopia is a rapidly escalating global health issue, with projections indicating that nearly 60% of North Americans could be affected by 2050. The condition can lead to severe, vision-threatening complications later in life, including glaucoma and retinal detachment. The absence of an FDA-approved pharmaceutical treatment in the U.S. highlights a critical gap in pediatric eye care.
The forthcoming FDA Advisory Committee meeting represents a pivotal moment for Sydnexis and the broader pediatric ophthalmology community. A favorable outcome could pave the way for the first approved pharmaceutical treatment for progressive myopia in the United States. This would address a significant unmet medical need and provide a standardized, accessible therapy for a condition affecting millions of children.